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ABSTRACT
Background: Data regarding outcome of Coronavirus disease 2019 (COVID-19) in patients with 
autoimmune hepatitis (AIH) are lacking.
Patients and methods: We performed a retrospective study on AIH patients with COVID-19 from 34 
centres in Europe and the Americas. We analyzed factors associated with severe COVID-19 outcomes 
defined as the need for mechanical ventilation, intensive care admission, and/or death. The outcomes 
of patients with AIH were compared to a propensity-score matched cohort of non-AIH patients with 
chronic liver diseases (CLD) and COVID-19. The frequency and clinical significance of new-onset 
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Results: We included 110 AIH patients (80%,female) with a median age of 49 (range:18–85) years at 
COVID-19 diagnosis. New-onset liver injury was observed in 37.1% (33/89) of the patients. Use of 
antivirals was associated with liver injury (p=0.041; odds ratio (OR) 3.36[1.05-10.78]) while 
continued immunosuppression during COVID-19 was associated with a lower rate of liver injury 
(p=0.009; OR 0.26[0.09-0.71]). The rates of severe COVID-19 (15.5% vs 20.2% p=0.231) and all-
cause mortality (10% vs 11.5%; p=0.852) were not different between AIH and non-AIH CLD. 
Cirrhosis was an independent predictor of severe COVID-19 in patients with AIH (p<0.001; OR 
17.46[4.22-72.13]). Continuation of immunosuppression or presence of liver injury during COVID-19 
was not associated with severe COVID-19.
Conclusions: This international, multi-center study reveals that patients with AIH were not at risk for 
worse outcomes with COVID-19 than other causes of CLD. Cirrhosis was the strongest predictor for 
severe COVID-19 in AIH patients. Maintenance of immunosuppression during COVID-19 was not 
associated with increased risk for severe COVID-19, but did lower the risk for new-onset liver injury 
during COVID-19.
INTRODUCTION:
Coronavirus Disease 2019 (COVID-19), caused by the Severe Acute Respiratory Syndrome 
coronavirus 2 (SARS-CoV-2), was first described in December 2019 in Wuhan, China [1].  Following 
this first report, it rapidly spread world-wide and caused an international pandemic. Most COVID-19 
cases have mild symptoms but the disease can result in hospitalization, progression into respiratory 
failure and death [2-4]. Older age, cardiovascular diseases, chronic lung diseases, active cancer, 
obesity, and diabetes mellitus are risk factors for severe COVID-19 outcomes [5]. COVID-19 often 
affects the liver and individuals with underlying chronic liver diseases (CLD) have high rates of 
hospitalization and mortality [6-7]. 
Autoimmune hepatitis (AIH) is a chronic immune-mediated liver disease [8]. Corticosteroids alone or 
in combination with azathioprine is the standard therapy in AIH. Several alternative 
immunosuppressive drugs, including tacrolimus, mycophenolate mofetil (MMF), methotrexate, 6-
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standard therapy [8-9]. The majority of AIH patients require life-long immunosuppressive therapy, 
which may increase the risk of bacterial and viral infections [8]. Existing data regarding the clinical 
presentation and outcome of COVID-19 in patients with AIH is limited to small case series and expert 
opinions [10-11]. The stage of liver disease has been shown to be risk factor, but it is unclear whether 
the type of underlying liver disease is a major contributing factor to poor outcomes with COVID-19. 
Specifically for AIH, immunosuppressive therapy enhances the risk of severe COVID-19. On the 
other hand it may be argued that immunosuppression protects against the inappropriate immune 
response, or cytokine storm, which is a characteristic of severe COVID-19 [12].
The aims of this international multi-centre study, were to assess the clinical characteristics and 
outcomes of AIH patients infected with COVID-19 and to explore the frequency and factors 
associated with new-onset liver injury and severe COVID-19 outcome in these patients.
MATERIALS AND METHODS
Study design
We retrospectively evaluated data of AIH patients who were diagnosed with COVID-19 between 
March 11 and November 12, 2020 from 34 centres in 10 countries. All participants independently 
identified patients and collected data from electronic health records and patient’s follow-up charts. 
Patients with AIH who were older >16 years at the time of COVID-19 with a diagnosis confirmed by 
a PCR based test were included in the study. Patients with typical radiological findings but with 
negative PCR tests were not included. All patients with AIH, or overlap with primary biliary 
cholangitis (PBC) or primary sclerosing cholangitis (PSC), were diagnosed and treated according to 
international guidelines [8,13].
The presence of cirrhosis was diagnosed based on standard imaging studies (elastography, ultrasound, 
computerized tomography or magnetic resonance), liver tissue examination or clinical findings of 
portal hypertension or its complications. Complete biochemical response was defined as normal ALT, 
AST and immunoglobulin G (IgG) levels. Partial response was defined as a decrease of ALT or AST 
to below two times the upper normal limit (UNL) and non-response was defined as persistently 
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therapy [8,13]. High alcohol consumption was defined as a more than 2 drinks/day for men and more 
than 1 drink/day for women [14].
New-onset liver injury was defined as rising ALT values during COVID-19 and categorized as no or 
mild (<2xULN), moderate (2-5xULN) or severe (>5xULN). New-onset ALT >2xULN was used as 
definition of liver injury for the study. Patients who were non-responders to AIH therapy were 
excluded from new-onset liver injury analysis as they already had ALT >2xULN levels before the 
COVID-19 diagnosis. The cut offs for normal values of ALT were considered 25 U/L for women and 
35 U/L for men [15]. Severe COVID-19 infection was defined as a composite of intensive care unit 
(ICU) admission, ventilator use and/or death in line with previously reported COVID-19 data [3]. The 
Harran University Hospital of Şanlıurfa was the coordinating centre (HRE ID 2020-00682) and local 
ethical review boards of participating centres approved the study.
Data collection 
Collected patient data included general information of patients, autoimmune liver serology, types and 
doses of immunosuppression, patient’s AIH response status at last follow-up before COVID-19 and 
presence of cirrhosis. At the time of COVID-19 diagnosis, body mass index (BMI), clinical features, 
and co-morbid conditions were recorded. Laboratory values at COVID-19 diagnosis and at 
peak/worst values any time in the first month of COVID-19 were used to evaluate liver injury. Any 
modification in the dose or type of immunosuppressive drugs during COVID-19, highest care level, 
hospitalization time, specific COVID-19 therapies and patient outcomes, providing a minimum of 
four weeks after COVID-19 were recorded. 
In order to determine how AIH impacts clinical outcomes with COVID-19, we compared AIH 
patients to a control group of patients with non-AIH CLD and COVID-19. To identify a control 
group, we used data from a multi-center, observational study of adult patients with CLD and PCR-
confirmed COVID-19. More details regarding the inclusion and exclusion criteria of this cohort have 
been previously published [7]. Only non-AIH patients from this cohort were included in the control 
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Continuous variables were presented as mean with standard deviation, or as median with range. 
Student’s t-test or the Mann-Whitney U test was used for comparisons, as appropriate depending on 
the distribution. Categorical variables were presented as numbers and percentages, and the chi-
squared test was used for comparisons. Multivariable logistic regression analysis models were 
performed to predict the two major outcomes of the study (dependent variables): significant new-
onset liver injury and severe COVID-19. According to the predefined statistical plan, we evaluated 
associations between each independent variable and outcome after having analysed the number of 
outcome events. In addition to predefined sex and age in terms of their clinical relevance for the 
outcomes, independent variables with a statistically significant relationship (P < 0.1) with dependent 
(outcome) variables in the univariate analysis were then included in the multivariable models. 
Hosmer–Lemeshow goodness-of-fit statistics were used to assess model fit. A p-value < 0.05 was 
considered to represent statistical significance. 
We compared clinical outcomes of COVID-19 in patients with AIH and non-AIH CLD. We used 
propensity score analysis to identify a cohort of patients with non-AIH CLD and COVID-19 who 
were statistically matched on a 1:2 basis using the nearest neighbor approach. We matched the AIH 
and non-AIH for crucial variables which are known to impact clinical outcomes with COVID-19 
including age, gender, presence of cirrhosis, diabetes mellitus hypertension and heart diseases.
RESULTS
General characteristics of the study population
Medical data of 115 patients AIH who acquired COVID-19 was analyzed. Five patients were 
excluded: three patients had previously undergone liver transplantation and two patients were 
concomitantly diagnosed with AIH and COVID-19 (Figure 1). The final study group included 110 
AIH patients (80%, female) with a median age of 49 (range 18–85) years at COVID-19 infection. 
Four of these patients had been included in a previous study [11]. The general characteristics, clinical 
features and outcomes of the patients are presented in table 1. Twelve (10.9 %) patients had overlap 
with PBC and four (3.6%) with PSC. Co-existence of other immune mediated disorders were noted in 
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bowel diseases in three (2.7%), Sjögren syndrome in two (1.8%), systemic sclerosis in two (1.8%), 
rheumatoid arthritis in two (1.8%), systemic lupus erythematosus in one (0.9%), celiac disease in one 
(0.9%), ankylosing spondylitis in one (0.9 %) and anti-phospholipid syndrome in one (0.9%). 
AIH characteristics before COVID-19
At last follow-up before COVİD-19 diagnosis, 88 (80%) patients were complete responders, 19 
(17.3%) were partial responders and three (2.7%) were non-responders. Thirty-two (29.1%) patients 
with AIH had features of cirrhosis. A total of 53 (48.2%) patients had co-morbid conditions; diabetes 
mellitus (n=27, 24.5%) and hypertension (n=26, 23.6%) were the most common. Seven (6.4%) 
patients reported active smoking and two (1.8%) had high alcohol consumption. Five (4.5%) patients 
had a history of malignancy, two of which were active during COVID-19. 
Most patients (92.7%) were on immunosuppressive therapy prior to the COVID-19 diagnosis. Eight 
patients (7.3%) were not on immunosuppressive therapy; six patients had withdrawn therapy (three by 
themselves and three by a physician), one patient was non-responder to available therapies and one 
had inactive (“burned-out”) cirrhosis. At the time of COVID-19 diagnosis, 65 (59.1%) patients were 
on prednisone therapy (alone or in combination with other immunosuppressants) with median dose of 
5 (range 2.5-60) mg/ day. Among them, 25 (22.7%) patients were on prednisone ≥10 mg/day therapy. 
The patients’ immunosuppressive therapies are presented in table 1.
Management of AIH during COVID-19 
Majority of patients (n=96, 87.3%) were symptomatic at the time of COVID-19 diagnosis; cough 
(n=68, 61.8%) and fever (n=65, 59.1%) were the most commonly reported symptoms. 
Gastrointestinal symptoms (abdominal pain, diarrhea, nausea and vomiting) were noted in 30 (27.2%) 
patients. 
The dose or type of immunosuppression was modified in 33 (30%) patients during COVID-19, but 
remained unchanged in 69 (62.7%). General characteristics of the patients according to 
immunosuppressive therapy status are presented in table 2. Among patients on azathioprine/6-MP 
monotherapy (n=10), doses were reduced in three and discontinued in seven. Among patients on 
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with a combination of azathioprine/6-MP and steroids (n=14), the dose of only azathioprine/6-MP 
was reduced in one and discontinued in five, and the dose of only steroids was reduced in five, while 
the doses of both azathioprine/6-MP and steroids were reduced in one patient and discontinued in two 
patients. Azathioprine was discontinued and tacrolimus reduced in a patient who was treated with 
both drugs. In one patient who was on triple immunosuppression, azathioprine was discontinued and 
both the steroid and tacrolimus doses were reduced. Among patients treated with MMF and steroids 
(n=4), only MMF was discontinued in three and both drugs were reduced in one patient. The dose was 
reduced in a patient on MMF monotherapy. 
Antibiotics were given to 40 (36.4%) patients during COVID-19 infection. Sixty-seven (60.9%) 
patients received specific therapy for COVID-19. Hydroxychloroquine (n=29, 26.4%) and antivirals 
(n=22, 20%) were the most commonly used therapies. High dose steroids were given to 15 (13.6%) 
patients and plasma exchange was performed in three (2.7%) patients. Tocilizumab and rituximab 
were used in one (0.9%) patient each. The details of COVID-19 therapies are presented in Table 1.
Liver injury during COVID-19
New-onset liver injury was reported in 37.1% (33/89) of the patients: 16 (18%) had moderate and 17 
(19.1%) had severe liver injury. New-onset liver injury was observed in 85.7% (6/7) of the patients 
who were not on immunosuppression, in 51.7% (15/29) of the patients whose immunosuppression 
was modified and in 22.6% (12/53) of the patients whose immunosuppression was unchanged during 
COVID-19. Predictors of liver injury are presented in Table 3. Multivariate regression analysis 
revealed that antivirals (defined in table 1) were associated with new-onset liver injury (p=0.041; odds 
ratio (OR) 3.36 [95% confidence interval (CI): 1.05-10.78]) and that continued immunosuppression 
during COVID-19 reduced the probability of liver injury (p= 0.009; OR 0.26 [0.09-0.71]). 
Outcomes of COVID-19 in patients with AIH compared to non-AIH CLD
When the outcomes of patients with AIH (n=110) were compared to a cohort of non-AIH patients 
with CLD (n=220) and COVID-19 (supplementary table 1), no statistically significant differences 
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(15.5% vs. 20.2%; p=0.231), need for supplemental oxygen (38.2% vs. 42.2%; p=0.553) and 
hospitalization (46.4% vs 50.0%; p=0.560) (Figure 2).
Seventeen AIH patients had severe COVID-19 and 11 patients died due to COVID-19. Predictors of 
severe outcomes in patients with AIH are presented in Table 4. After adjusting for age, gender, co-
existence of PBC/PSC or extrahepatic autoimmune diseases and AIH therapy response, the presence 
of cirrhosis was independently associated with severe COVID-19 (p<0.001; OR 17.46 [4.22-72.13]). 
AIH patients with comorbid conditions (defined in table 1) tended to have severe COVID-19 infection 
(p=0.06; OR 4.16 [0.94-18.36]). Presence of liver injury and continued immunosuppression during 
COVID-19 were not associated with severe COVID-19. 
DISCUSSION 
In this international multi-centre study, we evaluated the clinical presentation, laboratory features and 
outcomes of COVID-19 in patients with AIH. In our study population, 37.1% of the patients 
developed new-onset liver injury during COVID-19. Among 110 patients with AIH, 15.5% had 
severe COVID-19 and 10% of patients died. Our data show that i) the overall outcome of COVID-19 
was favorable in patients without cirrhosis; ii) on-going immunosuppression was not associated with 
increased risk of severe COVID-19 and iii) maintenance of immunosuppression was associated with a 
lower risk for new-onset liver injury.
We found similar rates of severe COVID-19 outcome and mortality in patients with AIH and a 
matched control group of non-AIH CLD and COVID-19. Among patients with AIH, patients with 
cirrhosis had higher risk for severe COVID-19 outcomes (43.8% vs. 3.9%). Overall mortality was 
also significantly higher in patients with cirrhosis than those without (31.3% vs. 1.3%). In line with 
our results, other studies reported 30-34% mortality rates in patients with cirrhosis [16-17]. These 
results suggest that regardless of aetiology, cirrhosis is a strong predictor of worse prognosis in 
patients with COVID-19. Consistent with previous reports [5], AIH patients with comorbid conditions 
in our study tended to have severe COVID-19.
New-onset liver injury was observed in 37.1% during COVID-19. Other studies have reported the rate 
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with CLD [19]. Liver injury was found to be predictor of poor outcome in these studies [7, 18-19]. In 
our AIH cohort, liver injury was not associated with adverse COVID-19 outcomes. There are several 
possible causes of liver injury in COVID-19 and all causes probably do not carry the same mortality 
risk [18, 20]. Patients who develop hepatocyte necrosis induced by systemic inflammatory response 
syndrome, or ischemic injury due to circulatory or respiratory failure, may have a higher mortality 
risk compared to those who have a drug induced liver injury or develop an AIH relapse. The similar 
outcomes of patients with and without liver injury in our study might be explained by the likely 
incidence of AIH relapse or drug-induced liver injury, both manageable causes of liver injury.  
Relapse of AIH following infection is a well-known phenomenon [14]. COVID-19 can trigger 
hyperstimulation of the immune system, an event associated with high serum levels of inflammatory 
cytokines and chemokines [12]. Four patients with AIH and non-severe COVID-19 had new-onset 
liver injury along with high IgG levels, thus suggesting they experienced AIH relapse rather than 
COVID-19 induced liver injury (Table 5). Development of various inflammatory or autoimmune 
conditions has been reported during or shortly after COVID-19 [12, 21]. Some case reports suggested 
that AIH presents for the first time during COVID-19 [21-22]. In fact, two patients in our cohort (both 
excluded), did receive their initial diagnosis of AIH during COVID-19. Overall, our results suggest 
that COVID-19 may be associated with new onset or flare of AIH, especially in patients whose 
immunosuppression is reduced.
A lack of clear data has made it difficult to make definitive recommendations for management of 
immunosuppression during COVID-19. In our study, the doses and types of immunosuppression were 
continued unchanged in 62.7% of the patients when they acquired COVID-19, and this was not 
associated with adverse COVID-19 outcomes. Two previous studies [19,23] also reported that 
continued immunosuppression did not increase the risk of severe COVID-19 in liver transplant 
recipients, only MMF usage was linked to severe COVID-19 outcome [23]. In our study, MMF was 
discontinued or reduced in 62.5% (5/8) of the patients who were on this drug. Also, therapy with 
prednisone (≥10mg/day) was associated with higher hospitalization rates in a rheumatology setting 
[24] and similar results were also reported in patients with inflammatory bowel disease [25]. 
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prednisone ≥10mg/day compared to patients on <10 mg/day (24 vs. 12.9%, p=0.211). Due to the low 
number of patients who were on ≥10 mg/day prednisone or MMF therapy, we cannot draw definitive 
conclusions about the associated risks. Of note, patients whose immunosuppressive therapy was 
modified during COVID-19 experienced higher rates of liver injury or AIH relapse than those in 
whom immunosuppressive therapy was not modified. Relapse of AIH due to reduction or withdrawal 
of immunosuppression during COVID-19 represents diagnostic and therapeutic challenges. Elevated 
aminotransferases may be misinterpreted as a marker for severe COVID-19 and lead to unnecessary 
hospitalizations. Induction therapy to achieve AIH remission requires higher doses of 
immunosuppression, which may adversely affect the outcome of COVID-19. Our results support 
maintaining immunosuppressive therapy during COVID-19.
We acknowledge that the retrospective nature of our study is a main limitation. However, given the 
unprecedented nature of the pandemic, and the low prevalence of AIH, we believe that our study 
offers valuable insights into the management of these patients. Another limitation is the possibility of 
selection bias since asymptomatic patients and those with mild disease were likely not included in our 
study. We have however included both out-patients and in-patients, and more than 50% our study 
population was out-patients. We also observed that some of the hospitalized patients had short 
hospital stay. Since patients with AIH were immunosuppressed, had concomitant co-morbid 
conditions and also due to lack information about appropriate use of immunosuppressive therapy 
during COVID-19, it is possible that patients were admitted out of caution and hospitalization may 
not necessarily reflect the severity of COVID-19. We also found that management and therapeutic 
strategies for COVID-19 vary significantly between centers and countries. To overcome these 
limitations, we used widely accepted clinical end-points of severe COVID-19 infection like ICU 
admission and need for mechanical ventilation [3,23,25].  
 Our study also has several strengths. We derived data from many hepatology centres across Europe 
and the Americas and this represents the largest cohort describing COVID-19 in AIH to date. 
Moreover, we collected detailed information on immunosuppression changes during the course of 
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Lastly, we have compared the AIH cohort with a matched non-AIH cohort which allows examining 
the impact of AIH itself on clinical outcomes of COVID-19. 
In conclusion, this large multi-centre study of AIH patients with COVID-19 found overall mortality 
and severe COVID-19 rates of 10% and 15.5%, respectively. Patients with AIH, despite being 
immunosuppressed, did not experience worse clinical outcomes with COVID-19 than patients with 
non-AIH CLD.  Presence of cirrhosis was the strongest predictor of severe COVID-19, and the 
overall outcome of COVID-19 was favorable in patients with non-cirrhotic AIH. Maintenance of 
immunosuppression was associated with lower risk of new-onset liver injury. We recommend that 
immunosuppression is not decreased or discontinued upon diagnosis of COVID-19.
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Table-1. Demographics, clinical features and outcome of study population (n=110)
Region
  
      North America, n (%) 34(30.9)
      South America, n (%)                        22(20)
      Europe, n (%) 54(49.1)
Sex (female), n (%) 88 (80)
Overlap syndromes (PBC/PSC), n (%) 12/4(10.9)/(3.6)
Concomitant autoimmune diseases, n (%) 28(25.5)
ANA, n (%)a 77 (76.5)
SMA, n (%)b 46 (45.1)
LKM-1, n (%)c 3(3.8)
LC-1, n (%)d 3(6.2)
SLA, n (%)e 2(4.1)
AIH activity at last visit before COVID-19
     Complete response, n (%) 88(80)
     Partial response, n (%) 19(17.3)
     Non-response, n (%) 3(2.7)
Presence of Cirrhosis, n (%) 32(29.1)
Features of AIH patients at COVID-19 infection
Age (years),  mean (SD) 47.9 (15.8)
Time from AIH diagnosis,  median (months) 60(1-480)
BMI, kg/m2, mean (SD) 26.5 (5.3)
Co-morbidities, (%) 53(48.2)
      Smoking 7(6.4)
      Alcohol 2(1.8)
      Hypertension 26(23.6)
      Diabetes 27(24.5)
      Coronary artery disease 5(4.5)
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      Heart failure 2(1.8)
      Respiratory disease 9(8.3)
      Cancer history 5(4.5)
      Kidney insufficiency 1(0.9)
Immunosuppressive therapy before COVID, n (%) 102(92.7)
      Azathioprine/6-MP 27 (24.5)
      Azathioprine/6-MP+Prednisolone/Budesonide 39 (35.4)
      Azathioprine/6-MP +Tacrolimus 1 (0.9)
      Azathioprine/6-MP+Prednisolone/Budesonide+ Tacrolimus 1 (0.9)
      Azathioprine/6-MP+Prednisolone/Budesonide+ Infliximab 1 (0.9)
      Azathioprine/6-MP+Prednisolone/Budesonide+ Vedolizumab 1 (0.9)
      Prednisolone/Budesonide 20 (18.1)
      Prednisolone/Budesonide+ Tacrolimus 2 (1.8)
     Prednisolone/Budesonide+ MMF 4 (3.6)
     Prednisolone/Budesonide+ Methotrexate 1 (0.9)
     Prednisolone/Budesonide+ Tacrolimus +MMF 1 (0.9)
     MMF 3 (2.7)
     Sirolimus 1 (0.9)
Symptoms at presentation, n (%) 96 (87.3)
     Fever 65 (59.1)
     Cough 68 (61.8)
     Dyspnoea 39 (35.5)
     Headache 22 (20)
     Fatigue and/or myalgia 65 (59.1)
     Anosmia 19 (17.3)
Gastrointestinal symptoms, n (%) 30 (27.2)
     Abdominal pain  11 (10)
     Diarrhea 13 (11.8)
     Nausea 7 (6.4)
     Vomiting 11 (10)
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Table-2. Characteristics of AIH patients according to immunosuppressive therapy 
status during COVID-19
Antibiotic therapy during COVID-19, n (%) 40 (36.4)
Medical therapies for COVID-19, n (%) 67 (60.9)
     Hydroxychloroquine 29 (26.4)
     Antivirals                       22(20)
   Favipiravir                       17(15.5)
   Remdesivir                         1 (0.9)
   Lopinavir/Ritonavir                         4 (3.6)
High dose steroids 15 (13.6)
Rituximab 1 (0.9)
Tocilizumab 1 (0.9)
Low molecular weight heparin 26 (23.6)
Plasma exchange 3 (2.7)
Oxygen therapy, n (%) 42 (38.2)
N          Nasal cannula 25 (22.7)
   Non-invasive ventilation/mechanical ventilation 9(8.2)/8(7.3)
New-onset liver Injury during COVID-19, n (%)f 33 (37.1)
Outcome of study population
Hospitalized, n (%) 51(46.4)
Intensive care admission, n (%) 15(13.6)
Death, n (%) 11(10)
ANA, antinuclear antibody; BMI,  body mass index; LC-1,  liver-cytosol type 1; LKM-1, liver kidney 
microsome type 1;  MMF, mycophenolate mofetil; MP, mercaptopurine;  PBC, primary biliary cholangitis; 
PSC, primary sclerosing cholangitis; SLA, soluble liver antigen; SMA, smooth muscle antibody. aANA was 
available in 101 patients; BMI was available in 83 bSMA was available in 101 patients; cLKM-1 was 
available in 80 patients; dLC1-1 was available in 48 patients; eSLA was available in 48 patients; fLiver 
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Age >65 (years) 13(18.8) 4(9.8) 0.278
Gender (female) 57(82.6)  31(75.6) 0.461
BMI>30 8(16.3) 8(23.5) 0.572
Co-morbidity 37(53.6) 18(43.9) 0.430
Cirrhosis 21(30.4) 11(26.8) 0.829
Remission before COVID-19 60(87) 28(68.3) 0.026
Symptoms at presentation 59(85.5) 37(90.2) 0.564
Treatment for COVID-19 43(62.3) 24(58.5) 0.840
*New-onset liver injury 12(22.6) 21(58.3) 0.001
Severe COVID-19 10(14.5) 7(17.1) 0.788
All-cause Mortality 4(5.8) 7(17.7) 0.096










This article is protected by copyright. All rights reserved
Table-3:Univariate and multivariate analyses of  new-onset liver injury in AIH patients with COVID-19 
Univariate analysis Multivariate analysis
OR 95% CI p value OR 95% CI p value
Sex (female) 1.21 0.37-3.93 0.742 1.85 0.42-8.05 0.407
Age (> 65 years) 0.56 0.16-1.94 0.364 0.76 0.18-3.10 0.704
BMI (>30) 2.05 0.62-6.75 0.235
Complete response to therapy 0.27 0.09-0.85 0.025 0.27 0.06-1.15 0.077
Cirrhosis 1.05 0.42-2.63 0.908
Co-morbidities 1.06 0.44-2.51 0.890
Immunosuppression maintenance 0.20 0.08-0.52 0.001 0.26 0.09-0.71 0.009
Antibiotics 1.64 0.68-3.91 0.263
Antivirals 3.00 1.06-8.49 0.039 3.36 1.05-10.78 0.041
Hydroxychloroquine 0.86 0.33-2.23 0.757
High dose steroid 0.82 0.25-2.65 0.742
O2 therapy (any) 2.56 1.06-6.20 0.037 2.23 0.81-6.13 0.118
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Table-4:Univariate and multivariate analyses for predictors of  severe COVID-19 in AIH patients 
Univariate analysis Multivariate analysis
OR 95% CI p value OR 95% CI p value
Sex (female) 1.19 0.31-4.59 0.792 2.20 0.44-10.82 0.330
Age (> 65 years) 2.81 0.84-9.40 0.093 1.03 0.23-4.48 0.964
Overlap of PBC/PSC 1.31 0.33-5.23 0.694
Extrahepatic autoimmune diseases 1.26 0.40-3.98 0.684
BMI (>30) 1.94 0.44-8.54 0.378
Co-morbidities 6.46 1.73-24.02 0.005 4.16 0.94-18.36 0.060
Prednisolone (≥10 mg) 2.12 0.70-6.48 0.192
Complete response to therapy 0.53 0.16-1.72 0.297
Cirrhosis 19.44 5.04-74.92 <0.001 17.46 4.22-72.13 <0.001
Immunosuppression maintenance 0.82 0.28-2.36 0.718
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Figure legends:
Table-5.Characteristics of AIH patients with features of disease relapse during COVID-19












1 F 60 AIH Complete Azathioprine, 50 mg/day, 
Prednisolone, 5 mg/day
Home 6.9/1.1 Azathioprine   
and prednisolone  
increased /Yes




6.8/1.7 MMF switched to 
tacrolimus /Yes
3 F 44 AIH Complete In remission without 
therapy
Home 4.3/1.2 Azathioprine and     
prednisolone 
added /Yes
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Figure 1: Study flow chart for patient inclusion. 
Figure 2: Clinical outcomes of COVID-19 in patients with AIH compared to non-AIH chronic liver 
disease. All-cause mortality (10% vs 11.5%), severe COVID-19 (15.5% vs 20.2%), need for 
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